Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
Belarus Frees 123 Political Prisoners in U.S.-Brokered Deal Over Sanctions 
U.S. Special Forces Intercept Ship Carrying Military Components Bound for Iran 
U.S. Lifts Sanctions on Brazilian Supreme Court Justice Amid Shift in Brazil Relations 
Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant 
Colombia’s Clan del Golfo Peace Talks Signal Mandatory Prison Sentences for Top Leaders 
Trump Signs Executive Order to Establish National AI Regulation Standard 
Trump Signals Two Final Candidates for Fed Chair, Calls for Presidential Input on Interest Rates 
Ukraine, US and Europe Seek Unified Peace Framework With Security Guarantees for Kyiv 
Brazil Arrests Former Peruvian Foreign Minister Augusto Blacker Miller in International Fraud Case 
Russian Drone Attack Hits Turkish Cargo Ship Carrying Sunflower Oil to Egypt, Ukraine Says 
Israeli Airstrike in Gaza Targets Senior Hamas Commander Amid Ceasefire Tensions 
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project 
Belarus Pledges to Halt Smuggling Balloons Into Lithuania 
Modi and Trump Hold Phone Call as India Seeks Relief From U.S. Tariffs Over Russian Oil Trade 
International Stabilization Force for Gaza Nears Deployment as U.S.-Led Planning Advances 
U.S. Soldiers Killed in ISIS Attack in Palmyra, Syria During Counterterrorism Mission 
Trump administration officials have reportedly explored ways to reduce the operational role of U.S. Food and Drug Administration (FDA) Commissioner Marty Makary, according to a Wall Street Journal report citing individuals familiar with internal discussions. The conversations, which allegedly involved Health Secretary Robert F. Kennedy Jr., focused on concerns over internal disputes among the commissioner’s top deputies and the overall management of the agency.
Sources claim Kennedy considered bringing in another senior leader to take charge of the FDA’s day-to-day responsibilities while keeping Makary in a more symbolic leadership position. The idea was intended to stabilize internal dynamics and strengthen the agency’s decision-making structure. However, officials have chosen to hold off on restructuring for now, giving Makary additional time to address leadership issues and improve cohesion within the FDA.
A White House spokesperson affirmed that the administration remains confident in both the Department of Health and Human Services and the FDA. The spokesperson emphasized that the agency, under Makary’s direction, continues to advance initiatives designed to support President Donald Trump’s commitment to “Make America Healthy Again,” highlighting efforts focused on improving public health and regulatory efficiency.
In a key leadership update, the FDA recently appointed renowned oncology expert Richard Pazdur to oversee the division responsible for regulating most prescription and over-the-counter medications. Pazdur’s appointment follows the resignation of George Tidmarsh earlier this month after concerns surfaced regarding his personal conduct, prompting the agency to accelerate leadership changes in this critical department.
As discussions about the FDA’s internal structure evolve, the administration appears intent on maintaining stability while pushing forward with major health and regulatory initiatives. Despite earlier considerations of reassigning responsibilities, officials now seem focused on giving Makary the opportunity to strengthen his leadership and guide the agency through ongoing reforms.
